Dendritic Spine Injury Induced by the 8-hydroxy Metabolite of Efavirenz

Overview

Journal J Pharmacol Exp Ther

Specialty Pharmacology

Date 2012 Sep 18

PMID 22984227

Citations 74

Authors

Luis B Tovar-y-Romo

Namandje N Bumpus

Daniel Pomerantz

Lindsay B Avery

Ned Sacktor

Justin C McArthur

Norman J Haughey

Affiliations

Soon will be listed here.

Abstract

Despite combination antiretroviral therapies (cARTs), a significant proportion of HIV-infected patients develop HIV-associated neurocognitive disorders (HAND). Ongoing viral replication in the central nervous system (CNS) caused by poor brain penetration of cART may contribute to HAND. However, it has also been proposed that the toxic effects of long-term cART may contribute to HAND. A better understanding of the neurotoxic potential of cART is critically needed in light of the use of CNS-penetrating cARTs to contend with the virus reservoir in the brain. The efavirenz (EFV) metabolites 7-hydroxyefavirenz (7-OH-EFV) and 8-hydroxyefavirenz (8-OH-EFV) were synthesized and purified, and their chemical structures were confirmed by mass spectrometry and NMR. The effects of EFV, 7-OH-EFV, and 8-OH-EFV on calcium, dendritic spine morphology, and survival were determined in primary neurons. EFV, 7-OH-EFV, and 8-OH-EFV each induced neuronal damage in a dose-dependent manner. However, 8-OH-EFV was at least an order of magnitude more toxic than EFV or 7-OH-EFV, inducing considerable damage to dendritic spines at a 10 nM concentration. The 8-OH-EFV metabolite evoked calcium flux in neurons, which was mediated primarily by L-type voltage-operated calcium channels (VOCCs). Blockade of L-type VOCCs protected dendritic spines from 8-OH-EFV-induced damage. Concentrations of EFV and 8-OH-EFV in the cerebral spinal fluid of HIV-infected subjects taking EFV were within the range that damaged neurons in culture. These findings demonstrate that the 8-OH metabolite of EFV is a potent neurotoxin and highlight the importance of directly determining the effects of antiretroviral drugs and drug metabolites on neurons and other brain cells.

Citing Articles

Neuroimaging advances in neurocognitive disorders among HIV-infected individuals.

Wang H, Jiu X, Wang Z, Zhang Y Front Neurol. 2025; 16:1479183.

PMID: 40017532 PMC: 11864956. DOI: 10.3389/fneur.2025.1479183.

Dolutegravir induces endoplasmic reticulum stress at the blood-brain barrier.

Huang C, Qu Q, Hoque M, Bendayan R FASEB J. 2025; 39(4):e70377.

PMID: 39985305 PMC: 11846018. DOI: 10.1096/fj.202402677RR.

Impact of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide on psychiatric symptoms and neurocognition.

Vergori A, Del Duca G, Lorenzini P, Brita A, Mastrorosa I, Fusto M AIDS. 2024; 39(3):270-275.

PMID: 39453875 PMC: 11784908. DOI: 10.1097/QAD.0000000000004043.

Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease Therapeutics.

Boyarko B, Podvin S, Greenberg B, Arnold S, Juanes A, van der Kant R ACS Pharmacol Transl Sci. 2024; 7(10):2924-2935.

PMID: 39421657 PMC: 11480897. DOI: 10.1021/acsptsci.4c00229.

Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial.

Oomen P, Hakkers C, Arends J, van der Berk G, Pas P, Hoepelman A Infect Dis Ther. 2024; 13(5):1067-1082.

PMID: 38642238 PMC: 11098980. DOI: 10.1007/s40121-024-00966-7.

References

Patel M, KO S, McHugh Jr R, Markwalder J, Srivastava A, Cordova B . Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett. 1999; 9(19):2805-10. DOI: 10.1016/s0960-894x(99)00486-2. View

Smurzynski M, Wu K, Letendre S, Robertson K, Bosch R, Clifford D . Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2010; 25(3):357-65. PMC: 3022370. DOI: 10.1097/QAD.0b013e32834171f8. View

Vivithanaporn P, Heo G, Gamble J, Krentz H, Hoke A, Gill M . Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology. 2010; 75(13):1150-8. PMC: 3013488. DOI: 10.1212/WNL.0b013e3181f4d5bb. View

Xu H, Bae M, Tovar-y-Romo L, Patel N, Bandaru V, Pomerantz D . The human immunodeficiency virus coat protein gp120 promotes forward trafficking and surface clustering of NMDA receptors in membrane microdomains. J Neurosci. 2011; 31(47):17074-90. PMC: 3254245. DOI: 10.1523/JNEUROSCI.4072-11.2011. View

Letendre S, Ellis R, Ances B, McCutchan J . Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010; 18(2):45-55. PMC: 5077300. View

Best B, Koopmans P, Letendre S, Capparelli E, Rossi S, Clifford D . Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2010; 66(2):354-7. PMC: 3019085. DOI: 10.1093/jac/dkq434. View

Heaton R, Clifford D, Franklin Jr D, Woods S, Ake C, Vaida F . HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010; 75(23):2087-96. PMC: 2995535. DOI: 10.1212/WNL.0b013e318200d727. View

Heaton R, Franklin D, Ellis R, McCutchan J, Letendre S, LeBlanc S . HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2010; 17(1):3-16. PMC: 3032197. DOI: 10.1007/s13365-010-0006-1. View

Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel K, Suda A . Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther. 2010; 88(5):676-84. DOI: 10.1038/clpt.2010.172. View

10.

Marra C, Zhao Y, Clifford D, Letendre S, Evans S, Henry K . Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009; 23(11):1359-66. PMC: 2706549. DOI: 10.1097/QAD.0b013e32832c4152. View

11.

Valcour V, Sithinamsuwan P, Letendre S, Ances B . Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep. 2010; 8(1):54-61. PMC: 3035797. DOI: 10.1007/s11904-010-0070-4. View

12.

Bumpus N, Kent U, Hollenberg P . Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther. 2006; 318(1):345-51. DOI: 10.1124/jpet.106.102525. View

13.

Langford T, Letendre S, Larrea G, Masliah E . Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol. 2003; 13(2):195-210. PMC: 4842209. DOI: 10.1111/j.1750-3639.2003.tb00019.x. View

14.

Tashima K, Caliendo A, Ahmad M, Gormley J, Fiske W, Brennan J . Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis. 1999; 180(3):862-4. DOI: 10.1086/314945. View

15.

Miksys S, Lerman C, Shields P, Mash D, Tyndale R . Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003; 45(1):122-32. DOI: 10.1016/s0028-3908(03)00136-9. View

16.

Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori M, Visco-Comandini U . Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007; 45(2):174-82. DOI: 10.1097/QAI.0b013e318042e1ee. View

17.

Clifford D, Evans S, Yang Y, Acosta E, Goodkin K, Tashima K . Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005; 143(10):714-21. DOI: 10.7326/0003-4819-143-10-200511150-00008. View

18.

Locuson C, Ethell B, Voice M, Lee D, Feenstra K . Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase. Drug Metab Dispos. 2008; 37(3):457-61. DOI: 10.1124/dmd.108.025312. View

19.

Schweinsburg B, Taylor M, Alhassoon O, Gonzalez R, Brown G, Ellis R . Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol. 2005; 11(4):356-64. DOI: 10.1080/13550280591002342. View

20.

Sacktor N, McDermott M, Marder K, Schifitto G, Selnes O, McArthur J . HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002; 8(2):136-42. DOI: 10.1080/13550280290049615. View